Standalone Drug Plans and Market Changes

Standalone Prescription Drug Plans (PDPs) face significant structural shifts heading into 2027. CMS concluded its temporary voluntary Part D Premium Stabilization Demonstration program, which previously subsidized private standalone plans.

Without these temporary federal stabilization subsidies, standalone PDP premiums will return to normal competitive market pricing in 2027. Private insurers must now price their plans based strictly on claims risk and operational costs.

Consequently, some standalone drug plans may raise monthly premiums, adjust copayment tiers, or narrow their pharmacy networks. Other carriers may choose to consolidate or exit specific regional markets entirely.

Retirees enrolled in Original Medicare with a standalone Part D plan must carefully review their annual renewal documents. Comparing alternative plans during open enrollment will be critical to avoid unexpected monthly premium hikes.

Advocacy resources from AARP emphasize that shopping your Part D coverage every year remains the best defense against rising plan premiums.

“A great retirement is one where you have peace of mind, not just a pile of money.” — Suze Orman, Personal Finance Author & Host